Preliminarily comparison of multiple radiographic modalities in evaluation of response to treatment of bone metastasis with Ra-223 - Comparison of radiographic modalities for Ra-223

ippon Medical School0 个研究点目标入组 30 人开始时间: 2020年1月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)Prior treatment within 1 week before enrollment or any combination use during the study with abiraterone and prednisone/prednisolone, enzalutamide, or chemotherapies (2)Prior hemibody external radiation (3)Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bone metastases within previous 24 weeks (4)Had history of gastrointestinal bleeding or ulcer within 3 months prior to study entry (5)Other malignancy treated prior to enrollment (except non-melanoma skin cancer or low-grade superficial bladder cancer) (6)History of visceral metastasis, or visceral metastases as assessed by screening imaging examination (7)Known brain metastasis (8)Malignant lymphadenopathy exceeding 3 cm in short-axis diameter (9)Imminent or established spinal cord compression based on clinical findings and/or MRI (Magnetic Resonance Imaging) (10)Any other serious illness or medical condition (11)Substance abuse, medical, psychological, or social conditions that might interfere with the subject's participation in the study or evaluation of the study (12)Those who have any contraindication to MRI or other Magnetic Imaging

发起方

ippon Medical School